Medicus Pharma Ltd.
(NASDAQ:MDCX) on Friday secured regulatory clearance from the United Arab Emirates Department of Health – Abu Dhabi for its PRECISION-E2 Phase 2a clinical study.
The trial evaluates Teverelix in women with moderate-to-severe symptomatic endometriosis, an estrogen-dependent disease affecting roughly 10% of reproductive-age women globally.
The trial marks a significant milestone in advancing a prospective genomics-guided precision medicine program designed to identify patients most likely to respond to a long-acting GnRH antagonist.
Read Also: EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study PRECISION-E2 Trial Design And Dosages The prospective, randomized, placebo-controlled Phase 2a study will evaluate Teverelix across multiple investigational sites in the UAE, enrolling approximately 84 women.
